Dr. Gasic [CRIS Cancer Foundation Breakthrough Scientist] aims to elucidate the “microtubule integrity response,” mechanisms that monitor the health of microtubules in cell division under normal physiological conditions and in cancer. Microtubules are frequent chemotherapy targets in treatment of various cancers, such as leukemia, lymphomas, melanoma, lung, ovarian, and breast cancer. Microtubule-targeting chemotherapeutics are believed to kill cancer cells through mitotic arrest. There is, however, growing evidence that they impact non-dividing “interphase” cells as well; this mechanism remains largely unexplored. She seeks to explore the microtubule integrity response, which may reveal how microtubule poisons kill non-dividing cancer cells, and help design better anti-cancer therapies.